Patents by Inventor Peter Astles

Peter Astles has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7947684
    Abstract: This invention relates to compounds of formula which inhibit Factor Xa or tryptase, to pharmaceutical compositions containing the compounds, and to the use of the compounds for the treatment of patients suffering from conditions which can be ameliorated by the administration of an inhibitor of Factor Xa or tryptase.
    Type: Grant
    Filed: July 8, 2003
    Date of Patent: May 24, 2011
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Heinz Pauls, Yong Gong, Julian Levell, Peter Astles, Paul R. Eastwood
  • Publication number: 20070054912
    Abstract: Compounds comprising an aza-bicyclic portion and an aromatic portion linked via an optionally oxidized sulphur atom are disclosed. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Application
    Filed: November 9, 2006
    Publication date: March 8, 2007
    Inventors: Peter Astles, Stephen Baker, Rowena Cube, Jose Martinez-Perez, Ana Mateo Herranz, Jean Vernier, Colin Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Sanderson, Colin Smith
  • Publication number: 20050228018
    Abstract: Provided herein are novel and useful compounds having a tryptase inhibition activity, pharmaceutical compositions comprising such compounds, and methods treating subjects suffering from a condition, disease, or disorder that can be ameliorated by the administration of an inhibitor of tryptase, e.g., asthma and inflammatory diseases, to name only a few.
    Type: Application
    Filed: February 14, 2005
    Publication date: October 13, 2005
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Peter Astles, Paul Eastwood, Olivier Houille, Julian Levell, Heinz Pauls, Mark Czekaj, Guyan Liang, Yong Gong, James Pribish, Kent Neuenschwander
  • Publication number: 20050182088
    Abstract: The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Application
    Filed: July 29, 2002
    Publication date: August 18, 2005
    Inventors: Peter Astles, Stephen Baker, Rowena Cube, Jose Martinez-Perez, Ana Mateo Herranz, Jean Vernier, Colin Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Sanderson, Colin Smith
  • Publication number: 20050070520
    Abstract: Compounds comprising an aza-cyclic portion and an aromatic portion linked via a sulphur atom are disclosed. The compounds disclosed are selective modulators of beta 4 subtype nicotinic acetylcholine receptors and are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Application
    Filed: July 29, 2002
    Publication date: March 31, 2005
    Inventors: Peter Astles, Stephen Baker, Celine Bonnefous, Jean Vernier, Martine Keenan, Adam Sanderson
  • Publication number: 20050038069
    Abstract: This invention is directed to physiologically active compounds of formula (I) wherein represents a bicyclic ring system, of about 10 to about 13 ring members, in which the ring is an azaheterocycle, and the ring represents an azaheteroaryl ring, or an optionally halo substituted benzene ring; R1 represents hydrogen or a straight- or branched-chain alkyl group of 1 to about 4 carbon atoms, optionally substituted by hydroxy or one or more halogen atoms, or when Z1 represents a direct bond R1 may also represent a lower alkenyl or lower alkynyl group, or a formyl group; R2 represents hydrogen, alkenyl, alkoxy, alkyl, alkylsulphinyl, alkylsulphonyl, alkylthio, aryl, arylalkyloxy, arylalkylsulphinyl, arylalkylsulphonyl, arylalkylthio, aryloxy, arylsulphinyl, arylsulphonyl, arylthio, cyano, cycloalkenyl, cycloalkenyloxy, cycloalkyl, cycloalkyloxy, heteroaryl, heteroarylalkyloxy, heteroaryloxy, hydroxy, —SO2NR4R5, —NR4SO2R5, —NR4R5, —C(?O)R5, —C(?O)C(?O)R5, —C(?O)NR4R5, —C(?O)OR5, —O(C?O)NR4R5, or
    Type: Application
    Filed: September 1, 2004
    Publication date: February 17, 2005
    Applicant: AVENTIS PHARMA LIMITED
    Inventors: Paul Cox, Shelley Bower, David Aldous, Peter Astles, Daniel McGarry, Christopher Hulme, John Regan, Fu-Chih Huang, Stevan Djuric, Kevin Moriarty, Rose Mathew, Gregory Poli
  • Publication number: 20040220171
    Abstract: This invention relates to compounds of formula 1
    Type: Application
    Filed: July 8, 2003
    Publication date: November 4, 2004
    Applicant: AVENTIS PHARMACEUTICALS INC
    Inventors: Heinz Pauls, Yong Gong, Julian Levell, Peter Astles, Paul R. Eastwood
  • Publication number: 20020045613
    Abstract: This invention relates to compounds of formula 1
    Type: Application
    Filed: April 24, 2001
    Publication date: April 18, 2002
    Inventors: Heinz Pauls, Yong Gong, Julian Levell, Peter Astles, Paul R. Eastwood
  • Patent number: 6124343
    Abstract: This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
    Type: Grant
    Filed: July 22, 1997
    Date of Patent: September 26, 2000
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Christopher Smith, Barry Porter, Roger Walsh, Tahir Majid, Clive McCarthy, Neil Harris, Peter Astles, Iain McLay, Andrew Morley, Andrew Bridge, Andrew Van Sickle, Frank Halley, Alan Roach, Martyn Foster
  • Patent number: 6048893
    Abstract: This invention is directed to compounds of formula I ##STR1## wherein R.sup.1 is CN, CH.sub.2 CN, CH.dbd.CHCN, CHO, or CH.dbd.CHCO.sub.2 H;R.sup.2 is aryl lower alkoxy, heteroaryl lower alkoxy, aryl lower alkylthio or heteroaryl lower alkylthio wherein each of the aryl and heteroaryl moieties is optionally substituted;R.sup.3 is halogen;R.sup.4 is optionally substituted aryl or optionally substituted heteroaryl;R.sup.5 is carboxy or an acid isostere;X is oxygen or sulphur; andn is zero or 1; or an N-oxide thereof, prodrug thereof solvate thereof, or pharmaceutically acceptable salt thereof, which compounds have endothelin antagonist activity. The invention is also directed to methods for preparing the compounds of formula I and their pharmaceutical use.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: April 11, 2000
    Assignee: Rhone-Poulenc Rorer Limited
    Inventors: Christopher Smith, Barry Porter, Roger Walsh, Tahir Majid, Clive McCarthy, Neil Harris, Peter Astles, Iain McLay, Andrew Morley, Andrew Bridge, Andrew Van Sickle, Frank Halley, Alan Roach, Martyn Foster